Moreover, CDK4 has been identified as oncogenic when alongside other genes and participates in the glycolytic process 48, and CDK4 itself was found to promote glycolysis 38 and potentially acts as a positive clinical prognostic marker for malignant phenotypes of HCC 39. This evidence concerns the gene CDK4 and hepatocellular carcinoma.